David J. Arthur - 03 Nov 2021 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fac
Issuer symbol
SLRX
Transactions as of
03 Nov 2021
Net transactions value
+$5,700
Form type
4
Filing time
05 Nov 2021, 14:58:04 UTC
Previous filing
17 Aug 2021
Next filing
21 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $5,700 +7,939 +7.8% $0.7180 110,186 03 Nov 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuantto the issuer's Employee Stock Purchase Plan.